On 29 July 2025, in a report to its shareholders, Celltrion announced that it has been designated as the preferred bidder for an undisclosed large-scale cGMP US manufacturing plant owned by a global pharmaceutical company. Celltrion is expecting to complete the acquisition in early October 2025.
According to Celltrion, the US manufacturing plant acquisition is part of its “US tariff response strategy”. Celltrion’s strategy to minimise the impact of “US pharmaceutical tariff policies” also includes stockpiling of two years’ worth of inventory within the US and expanding contracts with local CMO companies to enable US domestic production of products sold in the US.
Celltrion expects the acquisition of the US manufacturing facility to have additional benefits, including strengthening its market responsiveness and generating immediate revenue due to an agreement that will permit Celltrion to use half the plant’s capacity to exclusively produce the current plant owner’s biologics for the next 5 years.